Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related posts2024 Winter NewsletterJanuary 18, 2024Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2June 16, 20262023 Spring NewsletterApril 19, 2023 Previous post2026 Winter NewsletterNext postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis
